Managing Discovery In The Life Sciences: Harnessing Creativity To Drive Biomedical Innovation
by Mark V. Pauly /
2018 / English / PDF
15.7 MB Download
In this book, distinguished scholars Philip A. Rea, Mark V. Pauly,
and Lawton R. Burns explore the science and management behind
marketable biomedical innovations. They look at how the science
actually played out through the interplay of personalities, the
cultures within and between academic and corporate entities, and
the significance of serendipity not as a mysterious phenomenon but
one intrinsic to the successes and failures of the experimental
approach. With newly aggregated data and case studies, they
consider the fundamental economic underpinnings of investor-driven
discovery management, not as an obstacle or deficiency as its
critics would contend or as something beyond reproach as some of
its proponents might claim, but as the only means by which
scientists and managers can navigate the unknowable to discover new
products and decide how to sell them so as to maximize the
likelihood of establishing a sustainable pipeline for still more
marketable biomedical innovations.
In this book, distinguished scholars Philip A. Rea, Mark V. Pauly,
and Lawton R. Burns explore the science and management behind
marketable biomedical innovations. They look at how the science
actually played out through the interplay of personalities, the
cultures within and between academic and corporate entities, and
the significance of serendipity not as a mysterious phenomenon but
one intrinsic to the successes and failures of the experimental
approach. With newly aggregated data and case studies, they
consider the fundamental economic underpinnings of investor-driven
discovery management, not as an obstacle or deficiency as its
critics would contend or as something beyond reproach as some of
its proponents might claim, but as the only means by which
scientists and managers can navigate the unknowable to discover new
products and decide how to sell them so as to maximize the
likelihood of establishing a sustainable pipeline for still more
marketable biomedical innovations.